Navitoclax (ABT-263)

目录号：S1001

Molecular Weight(MW): 974.61

Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中K_i分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。

规格

价格

库存

购买数量

10mM/1mL In DMSO	RMB 3285.53	现货
5mg	RMB 975.71	现货
10mg	RMB 1631.61	现货
25mg	RMB 3016.58	现货
100mg	RMB 7950.36	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献153篇：

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Cell Metab, 2019, 30(1):129-142

PubMed: 31155496 ( click the link to review the publication )

Cancer Discov, 2018, 8(12):1598-1613

PubMed: 30254092 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(2):112-117

PubMed: 29200207 ( click the link to review the publication )

Cancer Cell, 2017, 32(4):490-505.e10

PubMed: 29017059 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):407-414.e4

PubMed: 28017795 ( click the link to review the publication )

Nature, 2016, 538(7626):477-482

PubMed: 27760111 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Sci Adv, 2019, 5(7):eaau9433

PubMed: 31392262 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e10769

PubMed: 31468706 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0775

PubMed: 31806643 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Thyroid, 2019, 29(4):540-548

PubMed: 30869573 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30860026 ( click the link to review the publication )

Oncogene, 2019, 38(1):47-59

PubMed: 30076411 ( click the link to review the publication )
Br J Pharmacol, 2019, 10.1111/bph.14773

PubMed: 31222722 ( click the link to review the publication )

J Med Chem, 2019, 62(15):6913-6924

PubMed: 31339316 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

FASEB J, 2019, 10.1096/fj.201900815RR

PubMed: 31408372 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):86

PubMed: 30867061 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31801186 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

J Biol Chem, 2019, 294(3):875-886

PubMed: 30482844 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:218

PubMed: 31462891 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:222

PubMed: 31467488 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

Cell Biosci, 2019, 9:60

PubMed: 31367332 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

Photodiagnosis Photodyn Ther, 2019, 10.1016/j.pdpdt.2019.08.016

PubMed: 31430575 ( click the link to review the publication )

Cancer Biomark, 2019, 24(1):51-59

PubMed: 30614795 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 42(3):287-301

PubMed: 30859392 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

J Allergy Clin Immunol, 2018, 142(5):1647-1650.e3

PubMed: 30048671 ( click the link to review the publication )

Nat Commun, 2018, 9(1):215

PubMed: 29335437 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10195-10215

PubMed: 30239926 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )
Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):713

PubMed: 29915306 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):21

PubMed: 29343814 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):907

PubMed: 30185782 ( click the link to review the publication )

Stem Cell Res Ther, 2018, 9(1):108

PubMed: 29669575 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Biochemical Pharmacology, 2018, 10.1016/j.bcp.2018.01.031

PubMed: ( click the link to review the publication )

Mar Drugs, 2018, 16(12)

PubMed: 30572618 ( click the link to review the publication )

Biomed Pharmacother, 2018, 107:139-145

PubMed: 30086460 ( click the link to review the publication )

Cell Cycle, 2018, 17(17):2175-2186

PubMed: 30198376 ( click the link to review the publication )

Toxicol In Vitro, 2018, 46:229-236

PubMed: 28947240 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1940

PubMed: 29208897 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2476-2487

PubMed: 28209615 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )
Mol Cancer Ther, 2017, 16(10):2178-2190

PubMed: 28611106 ( click the link to review the publication )

Cell Commun Signal, 2017, 15(1):16

PubMed: 28464919 ( click the link to review the publication )

Dis Model Mech, 2017, 10(9):1109-1115

PubMed: 28883017 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(12):1632-1641

PubMed: 28713162 ( click the link to review the publication )

Int J Oncol, 2017, 10.3892/ijo.2017.3914

PubMed: 28350129 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1141-1149

PubMed: 28885267 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Nat Microbiol, 2016, 1:15034

PubMed: 27572165 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996 ( click the link to review the publication )

Leukemia, 2016, 30(2):351-60

PubMed: 26488112 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Int J Cancer, 2016, 138(2):507-14

PubMed: 26260669 ( click the link to review the publication )

Anal Chem, 2016, 88(16):8050-7

PubMed: 27425825 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(1):35-45

PubMed: 26483423 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(11):2915-2926

PubMed: 27913811 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Cell Cycle, 2016, 15(3):394-402

PubMed: 26694174 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164250

PubMed: 27723829 ( click the link to review the publication )
Biochem Biophys Res Commun, 2016, 478(4):1792-7

PubMed: 27613092 ( click the link to review the publication )

J Biomol Screen, 2016, 21(7):680-8

PubMed: 27245141 ( click the link to review the publication )

Mol Med Rep, 2016, 13(1):403-11

PubMed: 26548896 ( click the link to review the publication )

Data Brief, 2016, 6:710-4

PubMed: 26958630 ( click the link to review the publication )

Oncotarget, 2016, 7(1):845-59

PubMed: 26625317 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

Ann Surg Oncol, 2015, 22(9):3079-86

PubMed: 25524010 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120913

PubMed: 25811469 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116998

PubMed: 25615615 ( click the link to review the publication )

Microvasc Res, 2015, 101:72-81

PubMed: 26122935 ( click the link to review the publication )

Oncol Lett, 2015, 10(2):829-834

PubMed: 26622578 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27388-402

PubMed: 26317541 ( click the link to review the publication )

Oncotarget, 2015, 6(17):15551-65

PubMed: 26036632 ( click the link to review the publication )

J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203 ( click the link to review the publication )
Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108371

PubMed: 25289887 ( click the link to review the publication )

PLoS One, 2014, ;9(6):e99404

PubMed: 24901320 ( click the link to review the publication )

Blood, 2013, 121(10):1850-7

PubMed: 23303820 ( click the link to review the publication )

Blood, 2013, 122(9):1587-98

PubMed: 23881917 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116 ( click the link to review the publication )

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e883

PubMed: 24157877 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Neoplasia, 2013, 15(5):568-78

PubMed: 23633928 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2960-8

PubMed: 23974105 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64051

PubMed: 23691145 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 434(3):695-700

PubMed: 23602897 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )
Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819 ( click the link to review the publication )

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522 ( click the link to review the publication )

Transfusion, 2012, 52(10):2094-103

PubMed: 22320126 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(12):3956-68

PubMed: 21652541 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24590

PubMed: 21931768 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444 ( click the link to review the publication )

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

产品描述

Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中K_i分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。

靶点

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

体外研究

ABT-263有效抑制Bcl-2蛋白家族，用荧光偏振分析法测试ABT-263作用于Bcl-xL, Bcl-2和 Bcl-w时，K_i分别为0.5, 1和1 nM。^[1]ABT-263结构上与ABT-737相关。ABT-263阻断Bcl-2 和Bcl-XL与凋亡前体蛋白相互作用。Bcl-2家族成员Bcl-2,Bcl-XL, 和Mcl-1的过量表达通常都与肿瘤的修复及抗药性有关。ABT-263作用于过量表达的Bcl-2 和Bcl-XL时显示出保护作用，EC50分别为60 和20 nM。ABT-263作用于不同的细胞显示出不同的细胞活性，作用于H146细胞系时EC50为110nM,而作用于H82细胞系时EC50为22 µM。ABT-737可以有效作用于四种EC50值 <400 nM的细胞系，即H146, H889, H1963, 和H1417。而两种抗ABT-737的细胞系，即H1048和H82，同样也显示出抗ABT-263的特性。^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	NHrkfVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPMRllKSzVyPUCuNFA3PjlizszN	MmD3V2FPT0WU
MV-4-11	MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XzR2lEPTB;MD6wNVU5PiEQvF2=	MWDTRW5ITVJ?
NKM-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGi0UW9KSzVyPUCuNFE3QTlizszN	NYnXe2lNW0GQR1XS
ML-2	Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorFTWM2OD1yLkCxPVg{KM7:TR?=	MWrTRW5ITVJ?
BV-173	Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVuxfZdEUUN3ME2wMlAzOzF2IN88US=>	NHfreWhUSU6JRWK=
RS4-11	M2LXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMEK1PFch\|ryP	MVHTRW5ITVJ?
HL-60	NUXicWFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\LPXV4UUN3ME2wMlAzQTB6IN88US=>	MWTTRW5ITVJ?
KY821	NHP1Z4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknUTWM2OD1yLkCyPVc2KM7:TR?=	M3LjWXNCVkeHUh?=
ECC10	Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\LSGlEPTB;MD6wN\|c6OiEQvF2=	MVjTRW5ITVJ?
NCI-H720	NX7CfnVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjDeGlKSzVyPUCuNFQxOTFizszN	NXn5SoI6W0GQR1XS
QIMR-WIL	NXnQTlFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XDNGlEPTB;MD6wOFI5PyEQvF2=	NHGxOIJUSU6JRWK=
KG-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwMES0PFYh\|ryP	MYTTRW5ITVJ?
TGW	NIHabVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXRS3dDUUN3ME2wMlA1PjN\|IN88US=>	M2rhcnNCVkeHUh?=
ATN-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW[wZW1FUUN3ME2wMlA1PzN\|IN88US=>	NVXpeFZFW0GQR1XS
RH-18	M4myS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUf3NFdqUUN3ME2wMlA3ODR6IN88US=>	NXj5OZJ[W0GQR1XS
EW-18	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGD1[VBKSzVyPUCuNFY5PDFizszN	M1PDeHNCVkeHUh?=
NB17	M4jk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3qwdmlEPTB;MD6wO\|EzPCEQvF2=	MknjV2FPT0WU
SK-NEP-1	Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3f2T2lEPTB;MD6wO\|IyOyEQvF2=	M4PvXHNCVkeHUh?=
P12-ICHIKAWA	NXz3SYhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXjfpVMUUN3ME2wMlA4Pzd6IN88US=>	NUDzNYZ1W0GQR1XS
KARPAS-45	NEfYTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnMS3FKSzVyPUCuNFc5OTVizszN	MkHBV2FPT0WU
EW-3	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX2zNWZ4UUN3ME2wMlA5ODV\|IN88US=>	NGfhUW1USU6JRWK=
NB13	M3TOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7XN4lKSzVyPUCuNFgzODNizszN	MVTTRW5ITVJ?
NCI-H209	M2HhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTBwMEi3NFQh\|ryP	NYrDN3hPW0GQR1XS
NCI-H1092	NIfQOpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTBwMUCyO\|Uh\|ryP	NWXMUlhOW0GQR1XS
NH-12	NHzTdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HORmlEPTB;MD6xNFc1PCEQvF2=	M1izO3NCVkeHUh?=
697	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3UPZFKSzVyPUCuNVA5OzlizszN	MojWV2FPT0WU
KE-37	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\TVGlEPTB;MD6xNVM4KM7:TR?=	M1;XXnNCVkeHUh?=
MOLT-4	Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwMUWxOlkh\|ryP	M3zERnNCVkeHUh?=
CHP-134	NYmxeXZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPV[5FHUUN3ME2wMlE3OzB4IN88US=>	MYHTRW5ITVJ?
D-283MED	NGLVTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfzRoc5UUN3ME2wMlE4Pjh4IN88US=>	MmTyV2FPT0WU
LU-135	NV6wfFRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXLTWM2OD1yLkG4OVUzKM7:TR?=	M3z3O3NCVkeHUh?=
LU-134-A	M{XGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XDU2lEPTB;MD6xPFY4OSEQvF2=	NHPTTpBUSU6JRWK=
EM-2	NHvqZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwMUm5NVgh\|ryP	MVfTRW5ITVJ?
LU-139	NE\uVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljKTWM2OD1yLkKwOFk5KM7:TR?=	M2\xV3NCVkeHUh?=
ALL-PO	NIf1R5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXhPGlKSzVyPUCuNlE6QDhizszN	NIXrNmVUSU6JRWK=
NB12	M{\zdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfkTWM2OD1yLkKzNVE2KM7:TR?=	NFjSOHVUSU6JRWK=
KP-N-YN	NF\zXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDLTWM2OD1yLkKzOVc{KM7:TR?=	M3i5XXNCVkeHUh?=
BEN	MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfHTWM2OD1yLkKzPVY5KM7:TR?=	MkfwV2FPT0WU
HCC1569	NX\PZXl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYL5OlZZUUN3ME2wMlI2OTB4IN88US=>	MYHTRW5ITVJ?
HuO9	MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMk[3NVUh\|ryP	NVG5UXl1W0GQR1XS
WM-115	NUP3RZZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDzbHB4UUN3ME2wMlI4PzN6IN88US=>	NXf2c4twW0GQR1XS
CCRF-CEM	NEK5R5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzoOndKSzVyPUCuN\|M2OjlizszN	NYnveW1TW0GQR1XS
IST-SL1	MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPsTWM2OD1yLkO1N\|Q{KM7:TR?=	MWHTRW5ITVJ?
BE-13	NGXhc5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXWTWM2OD1yLkO2OFU6KM7:TR?=	MXTTRW5ITVJ?
COR-L88	NUnEfY5lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwM{[1OEDPxE1?	M{nITXNCVkeHUh?=
DOHH-2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLyTWM2OD1yLkSxNFI{KM7:TR?=	M1HaVHNCVkeHUh?=
A704	NX3FTWlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV[xTGl{UUN3ME2wMlQzPjdizszN	NU[3dopVW0GQR1XS
KNS-81-FD	NV;UPHpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXpTWM2OD1yLkS0NFE4KM7:TR?=	M3ezS3NCVkeHUh?=
RPMI-8226	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwNEW2OVIh\|ryP	MVrTRW5ITVJ?
TGBC24TKB	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7kWpdKSzVyPUCuOFU4PzhizszN	MlTWV2FPT0WU
NCI-H1304	MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PvW2lEPTB;MD60OlE2PyEQvF2=	MVnTRW5ITVJ?
MOLT-13	NEfNTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Xod2lEPTB;MD60OlYyOyEQvF2=	NFfHOGdUSU6JRWK=
EW-22	M1fmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3ETWM2OD1yLkS2OlcyKM7:TR?=	M3j0PXNCVkeHUh?=
MS-1	NXrBUo1{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzpOnk{UUN3ME2wMlQ3QTN\|IN88US=>	MVHTRW5ITVJ?
RMG-I	M1Lzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwNEm0OlQh\|ryP	NW\6VY0yW0GQR1XS
NTERA-S-cl-D1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DzSGlEPTB;MD61NFAyQSEQvF2=	NYPTe\|RNW0GQR1XS
NCI-H1048	NWj2U2xYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTEXoV[UUN3ME2wMlUxQTV\|IN88US=>	MVTTRW5ITVJ?
SW1417	M2f2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;HNIJKSzVyPUCuOVU1OzhizszN	NIL5WW5USU6JRWK=
DB	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWC0V4t{UUN3ME2wMlU4ODhizszN	NHnDOVRUSU6JRWK=
MEG-01	NGP3cGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwNUizNkDPxE1?	MVTTRW5ITVJ?
EW-13	Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PtOWlEPTB;MD61PFM1OSEQvF2=	MmXrV2FPT0WU
LAMA-84	NX73Unh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTBwNUmyNFch\|ryP	MUXTRW5ITVJ?
J-RT3-T3-5	NVi4[\|dET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHvTWM2OD1yLk[wPFA5KM7:TR?=	NV7ueXJ7W0GQR1XS
MOLT-16	NHT1N2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvEfIdKSzVyPUCuOlUzPjRizszN	NUm3TFRpW0GQR1XS
DU-4475	M4TDc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjRTWM2OD1yLk[1OFI4KM7:TR?=	Mn;hV2FPT0WU
HAL-01	MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{WzW2lEPTB;MD63NlU1QSEQvF2=	M4GxbnNCVkeHUh?=
RD	NFfVVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3npcmlEPTB;MD63OVg6QSEQvF2=	M{jlN3NCVkeHUh?=
OAW-28	MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTBwN{izO{DPxE1?	NW[wN452W0GQR1XS
HCC38	M13GO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;rTWM2OD1yLkiwNVkh\|ryP	MnPHV2FPT0WU
NMC-G1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXSTWM2OD1yLkixNVIyKM7:TR?=	NXvFb5RCW0GQR1XS
EW-16	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo[1TWM2OD1yLkixN\|I5KM7:TR?=	NHHFRVBUSU6JRWK=
DU-145	M{XhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTk[GxKSzVyPUCuPFk6OjNizszN	MYPTRW5ITVJ?
HPAF-II	M3TNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXyPYJnUUN3ME2wMlkzPjJ6IN88US=>	NUK4NFVUW0GQR1XS
A427	MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjMbpFKSzVyPUCuPVMxOjJizszN	MWDTRW5ITVJ?
PA-1	NWP1Z\|I3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3aWHhFUUN3ME2wMlk2PjR{IN88US=>	NVvQOlFUW0GQR1XS
OAW-42	NYLnOmx{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwOU[xOFYh\|ryP	M2LLNHNCVkeHUh?=
L-428	MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLiTWM2OD1zLkCxNlUh\|ryP	M2XDfHNCVkeHUh?=
COLO-824	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIS3NWFKSzVyPUGuNFE4ODhizszN	M4XveHNCVkeHUh?=
P30-OHK	NWHNNmdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTFwMES2PFgh\|ryP	MoHqV2FPT0WU
NCI-H2170	Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrjWld6UUN3ME2xMlA3OjNizszN	NWn3WZhRW0GQR1XS
HCC2998	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LWXWlEPTB;MT6wO\|E{PSEQvF2=	NWTJW\|hVW0GQR1XS
NB14	M3XJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjmN\|IzUUN3ME2xMlE{PzR6IN88US=>	M1fubnNCVkeHUh?=
TGBC1TKB	NXLGOpJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTFwMUSxOVIh\|ryP	MXLTRW5ITVJ?
KP-N-YS	NFjXZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLWTWM2OD1zLkG2NlM3KM7:TR?=	M1XFbXNCVkeHUh?=
CAL-120	Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPaRXBKSzVyPUGuNVY1OjlizszN	NXLUWoJJW0GQR1XS
SBC-1	NIDhRnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\RNWlEPTB;MT6xPVA2OyEQvF2=	NWPoXol[W0GQR1XS
C32	M163O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXhPWN{UUN3ME2xMlE6ODh6IN88US=>	NUHQc3ZxW0GQR1XS
HCC2157	NUmyd3FiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7KTWM2OD1zLkG5OFk1KM7:TR?=	NXr6[JB3W0GQR1XS
COLO-792	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nZR2lEPTB;MT6yNFA4OSEQvF2=	NWrSV2hlW0GQR1XS
ES7	M1TwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTFwMke5OVEh\|ryP	NEfiN\|hUSU6JRWK=
HEL	MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTFwM{GwNlkh\|ryP	MVHTRW5ITVJ?
ES4	NVviV2Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;vVmlEPTB;MT6zOFk6QCEQvF2=	MUjTRW5ITVJ?
NCI-SNU-1	NG[4WplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfVSmJZUUN3ME2xMlM3PTV3IN88US=>	NXzINVZmW0GQR1XS
MDA-MB-415	NXPvdmZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXu1ZWZKUUN3ME2xMlM5QDVizszN	M4D5[3NCVkeHUh?=
NCI-H2342	NYHNW5F[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nt[mlEPTB;MT60NFI3QSEQvF2=	NFr5UHNUSU6JRWK=
NB69	Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTxW3htUUN3ME2xMlQ3OjdzIN88US=>	MWXTRW5ITVJ?
D-247MG	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;qV2hKSzVyPUGuOVEyOjJizszN	MUnTRW5ITVJ?
SCC-4	M{DmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTFwNUm4PFch\|ryP	NWXXfFBGW0GQR1XS
HuH-7	M1PIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLHNXd1UUN3ME2xMlY4Ojl\|IN88US=>	MoW1V2FPT0WU
A388	NHPKeZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDndHZKSzVyPUGuOlg4OjRizszN	MmPkV2FPT0WU
Calu-3	NUHQVFFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TNV2lEPTB;MT63NFY6PyEQvF2=	MXXTRW5ITVJ?
NCI-H1648	M2fzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fzTWlEPTB;MT63NVQyQCEQvF2=	M3nwVnNCVkeHUh?=
NCI-H2052	Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3q4e2lEPTB;MT63NlIxOSEQvF2=	M1fsfnNCVkeHUh?=
Ramos-2G6-4C10	Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTFwN{O2OVYh\|ryP	NV7PZpZkW0GQR1XS
DEL	Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVm3XYNlUUN3ME2xMlc1Pjl{IN88US=>	NWH3SIhnW0GQR1XS
SNU-423	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDZTWM2OD1zLke4NVU4KM7:TR?=	MknDV2FPT0WU
COR-L23	MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjFWJhqUUN3ME2xMlc6QDd2IN88US=>	MVTTRW5ITVJ?
OMC-1	Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULEUIVNUUN3ME2xMlg3ODF4IN88US=>	MVfTRW5ITVJ?
EW-11	NVnXUmx{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1K1fWlEPTB;MT65OVY2PyEQvF2=	MWLTRW5ITVJ?
HSC-3	NI\FT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\NdmlEPTB;MT65OlM3PSEQvF2=	MY\TRW5ITVJ?
MLMA	M1XxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fRXmlEPTB;MT65OlY4PyEQvF2=	MmToV2FPT0WU
RCM-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTJwMECzPVkh\|ryP	Mmn0V2FPT0WU
MFE-280	NFjsRYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUm2TppKUUN3ME2yMlAzQDR6IN88US=>	NFzH[HNUSU6JRWK=
ES8	NFXCU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml:wTWM2OD1{LkK1OFcyKM7:TR?=	MYHTRW5ITVJ?
TE-11	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;tTWM2OD1{LkK5OFc{KM7:TR?=	MVjTRW5ITVJ?
HuO-3N1	MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoeyTWM2OD1{LkS4O\|gh\|ryP	NES0W29USU6JRWK=
MHH-NB-11	MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTJwNUGxOVgh\|ryP	MnzBV2FPT0WU
TGBC11TKB	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDYTWM2OD1{LkW3OlgyKM7:TR?=	NF[xb5pUSU6JRWK=
HOP-92	Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmG0TWM2OD1{LkW4O\|Q{KM7:TR?=	MmPxV2FPT0WU
IGR-1	NFn3[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPKTWM2OD1{Lk[yNFM2KM7:TR?=	NGr5[W5USU6JRWK=
GOTO	NXfkbGlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rObWlEPTB;Mj62OVM4PyEQvF2=	Mm\PV2FPT0WU
NCI-H1650	MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTJwN{KyNVUh\|ryP	MUPTRW5ITVJ?
NCI-H1581	NE\MWZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTJwN{m2PFEh\|ryP	NH;hPVBUSU6JRWK=
NCI-H2405	NUjZNYdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPRXZpOUUN3ME2yMlgzPzh{IN88US=>	MUDTRW5ITVJ?
U-118-MG	NFLqcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\Wfmh3UUN3ME2yMlk3PDlzIN88US=>	NVfHbFR4W0GQR1XS
DoTc2-4510	M136U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGCwXG1KSzVyPUOuNFE1OTdizszN	NULPfmc2W0GQR1XS
NCI-H596	M1fLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TYe2lEPTB;Mz6wOFk6PyEQvF2=	MnzTV2FPT0WU
MPP-89	NHPFVWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTNwMEW2OlYh\|ryP	M3TvbXNCVkeHUh?=
GCIY	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPlTWM2OD1\|LkKwOFkyKM7:TR?=	MWrTRW5ITVJ?
SW626	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTNwMkS1OFMh\|ryP	NWTMOI8{W0GQR1XS
OCI-AML2	NUjZXVVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\VTWM2OD1\|LkOxNlczKM7:TR?=	MmT6V2FPT0WU
NBsusSR	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTNwM{S5N\|gh\|ryP	M3HIW3NCVkeHUh?=
AN3-CA	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzLUpBKSzVyPUOuOFQzOzhizszN	MoXQV2FPT0WU
EFM-19	MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknMTWM2OD1\|LkS4N\|M6KM7:TR?=	MnO3V2FPT0WU
RVH-421	M{LZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTNwNU[4O\|ch\|ryP	MYfTRW5ITVJ?
5637	NGXuUYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXHTWM2OD1\|Lk[xNVA{KM7:TR?=	NITmfoJUSU6JRWK=
PANC-08-13	Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULOcW53UUN3ME2zMlY{PDd{IN88US=>	NE[3[FBUSU6JRWK=
H9	MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfiTWM2OD1\|Lk[3NVQ1KM7:TR?=	M2PqRnNCVkeHUh?=
KARPAS-299	NHHMTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULhT2VVUUN3ME2zMlY4OzZzIN88US=>	MlTkV2FPT0WU
TE-5	M1;G[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnxTFRkUUN3ME2zMlcxPzB7IN88US=>	MYnTRW5ITVJ?
NOS-1	Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHxb4dKSzVyPUOuO\|k5OzRizszN	NXTWWIlFW0GQR1XS
HH	NGr0[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHS5VG9KSzVyPUOuPFM5PjhizszN	NEPCe2hUSU6JRWK=
769-P	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPCTWM2OD1\|Lki5OVEh\|ryP	MoiyV2FPT0WU
CHP-212	M{H5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M365fmlEPTB;Mz65NlU1QSEQvF2=	MWnTRW5ITVJ?
NCI-H82	Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoewTWM2OD1\|Lkm1PVM3KM7:TR?=	MVLTRW5ITVJ?
Mo-T	Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnwW5hKSzVyPUSuNFQ{OTJizszN	MWPTRW5ITVJ?
BB65-RCC	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TTU2lEPTB;ND6wOFM6QSEQvF2=	NFnNVnNUSU6JRWK=
SW1990	Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnSd3VKSzVyPUSuNFU6ODhizszN	MXrTRW5ITVJ?
LK-2	NUnMdG9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTRwMUGyPVMh\|ryP	NY\GT21IW0GQR1XS
ES5	NWe0[HdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmH1TWM2OD12LkGzPVg2KM7:TR?=	NWDoO5FJW0GQR1XS
JVM-3	M{fwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17BSGlEPTB;ND6xPFIzOiEQvF2=	MoXHV2FPT0WU
RPMI-7951	M1TPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXrTWM2OD12LkKyOFE{KM7:TR?=	MlPlV2FPT0WU
Calu-6	NEG5[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\iXGlEPTB;ND6yO\|g5OSEQvF2=	MnSzV2FPT0WU
LC-2-ad	Mo\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX:xU\|ByUUN3ME20MlI6PTZ6IN88US=>	NEPNRoZUSU6JRWK=
SW954	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTRwMkm2OkDPxE1?	M1nHZ3NCVkeHUh?=
H-EMC-SS	NYfaTYVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHBTWM2OD12LkOxPFMyKM7:TR?=	MWHTRW5ITVJ?
ES3	NYfDV\|FoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XOVGlEPTB;ND6zOVQ1OSEQvF2=	NVu1NXJyW0GQR1XS
no-11	NW\PPWpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DVcGlEPTB;ND6zOVU2PCEQvF2=	MUXTRW5ITVJ?
LAN-6	NIDKdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zX[GlEPTB;ND60OVE5QSEQvF2=	NEfrUnNUSU6JRWK=
FTC-133	NFHPNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXT6bJg3UUN3ME20MlU{QTVizszN	NV;1V5lIW0GQR1XS
8505C	NV3ndXVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fJO2lEPTB;ND61OFI{KM7:TR?=	MnrVV2FPT0WU
SW620	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLHTnpbUUN3ME20MlU4ODV5IN88US=>	MUTTRW5ITVJ?
BCPAP	NXzUVYUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrZTWM2OD12Lk[zOFgyKM7:TR?=	MXfTRW5ITVJ?
SK-LU-1	NGPIZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnWW4RKSzVyPUSuOlYxQDlizszN	M2DkXHNCVkeHUh?=
NCI-H1623	MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLLTWM2OD12LkewNlI5KM7:TR?=	NIDk[XpUSU6JRWK=
C2BBe1	NEXSPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnaNXJKSzVyPUSuO\|QxODhizszN	M4nNZnNCVkeHUh?=
GP5d	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3v6OGlEPTB;ND63PFM5QCEQvF2=	NGX1cHBUSU6JRWK=
NB6	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY[2VWdnUUN3ME20Mlg3OjB2IN88US=>	NVzNUJRYW0GQR1XS
MDA-MB-157	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTRwOEi3OkDPxE1?	M3Ph[HNCVkeHUh?=
UMC-11	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\XNI16UUN3ME20Mlg5QTZ2IN88US=>	MVTTRW5ITVJ?
HCC1419	MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTRwOUCwOlMh\|ryP	NXz4dWozW0GQR1XS
NCI-H2029	NH3GdYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\UTWM2OD12Lkm0NVg2KM7:TR?=	Ml;3V2FPT0WU
LXF-289	NWrFOFUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13D[WlEPTB;NT6wN\|cyQSEQvF2=	M1O2VHNCVkeHUh?=
KINGS-1	NFH4[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;MTWM2OD13LkC3O\|Q1KM7:TR?=	MVTTRW5ITVJ?
HD-MY-Z	NIrQ[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLnTWM2OD13LkKzPVY6KM7:TR?=	NH\HT41USU6JRWK=
ESS-1	NVjmXVdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nPXWlEPTB;NT6yOVU6PyEQvF2=	M1uwe3NCVkeHUh?=
GI-1	NGC0[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vwfGlEPTB;NT6yO\|kzPiEQvF2=	MlnFV2FPT0WU
RPMI-2650	NH3ZPIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2n0dWlEPTB;NT6zOlE3KM7:TR?=	M3\sXnNCVkeHUh?=
IA-LM	NY\FbnA5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITjVZdKSzVyPUWuN\|k5PzFizszN	MXPTRW5ITVJ?
KP-4	M4HS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fLcGlEPTB;NT60OlM{PCEQvF2=	MmfYV2FPT0WU
G-402	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTwZllKSzVyPUWuOVE5PjVizszN	MYXTRW5ITVJ?
OS-RC-2	NYXzTo12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPZTZFUUUN3ME21MlUzPjB2IN88US=>	M2rZbnNCVkeHUh?=
NCI-H1155	M4\ZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4ftW2lEPTB;NT61OFk2PSEQvF2=	NYDGb4ZRW0GQR1XS
OE19	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEP0bYZKSzVyPUWuOlg3OjRizszN	MmLzV2FPT0WU
U-2-OS	Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmC2TWM2OD13Lki5NFE{KM7:TR?=	NXvoV\|UzW0GQR1XS
SCC-15	M4jN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTVwOUO2OlIh\|ryP	NV:5NY9zW0GQR1XS
NCI-H630	NWHkZ2tST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPwepBKSzVyPUWuPVk1ODRizszN	MmTNV2FPT0WU
PFSK-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTZwMEWyOVkh\|ryP	M3XJN3NCVkeHUh?=
NCI-H1770	NIfKZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTZwMkC4O\|Qh\|ryP	Mmq4V2FPT0WU
SK-MEL-3	NITIUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDlNYRiUUN3ME22MlQzQTF3IN88US=>	NHrQb29USU6JRWK=
LB1047-RCC	NFOySpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7XcHlKSzVyPU[uOFc3OjVizszN	MXjTRW5ITVJ?
NCI-H446	M17QTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\CTWM2OD14Lk[yPVI2KM7:TR?=	MoDRV2FPT0WU
SW780	M{Wy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXre4FKSzVyPU[uO\|AyQDVizszN	MlXmV2FPT0WU
NEC8	Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTCTWM2OD14Lke2OlMh\|ryP	M2PwcXNCVkeHUh?=
NOMO-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLETWM2OD14Lke4NVEyKM7:TR?=	NGrTd3ZUSU6JRWK=
COLO-668	NVv6RZpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTuTWM2OD14Lki0N\|g4KM7:TR?=	M4rPc3NCVkeHUh?=
MC116	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;QNmlEPTB;Nj65N\|g6PyEQvF2=	MUXTRW5ITVJ?
HCC1937	NHXIWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvVeGFCUUN3ME22Mlk6OjVzIN88US=>	NEXoV21USU6JRWK=
NCI-N87	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTdwMUmyPVMh\|ryP	Mof3V2FPT0WU
COLO-320-HSR	MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTdwMkK3N\|gh\|ryP	NFToPVRUSU6JRWK=
HCC1806	NUHIZWJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3tTWM2OD15LkK2NFQ1KM7:TR?=	NGLvNFJUSU6JRWK=
OVCAR-3	M1vNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTdwM{OwN\|gh\|ryP	Mne0V2FPT0WU
NUGC-3	Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4[3emlEPTB;Nz6zPVY6PCEQvF2=	NF7HZpFUSU6JRWK=
SW1783	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXmb4hCUUN3ME23MlQ{OTd3IN88US=>	M4jZN3NCVkeHUh?=
GCT	NXi5XndQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDBdVd4UUN3ME23MlU3QTB4IN88US=>	M2mw[3NCVkeHUh?=
NCI-H2126	NXHBV5N4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTdwN{O2NlUh\|ryP	NH7ubmhUSU6JRWK=
MEL-HO	NGHvXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkS2TWM2OD15Lke3NFU1KM7:TR?=	MlnPV2FPT0WU
CAPAN-1	M1m5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zRWGlEPTB;Nz63O\|M2PyEQvF2=	NECzS5dUSU6JRWK=
SW756	NES3NVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTdwN{izN\|Mh\|ryP	M3r6NnNCVkeHUh?=
SKG-IIIa	M3rTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTqWm5VUUN3ME23MlgyQDl{IN88US=>	NVLYepcxW0GQR1XS
HCE-T	M1TNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjJTWM2OD15Lki3O\|g{KM7:TR?=	MXzTRW5ITVJ?
Ca-Ski	MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoCxTWM2OD15Lkm5N\|g{KM7:TR?=	NWDUbVVoW0GQR1XS
COLO-684	NUjrV29tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoK1TWM2OD16LkCxPFE5KM7:TR?=	MkLXV2FPT0WU
KYSE-70	NYDDeJB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\qPHJKSzVyPUiuNFc4OjlizszN	MonJV2FPT0WU
TI-73	MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{ntR2lEPTB;OD6yOVg2OSEQvF2=	M1PEcnNCVkeHUh?=
BT-20	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVv4dnBTUUN3ME24MlI3ODV{IN88US=>	NYfRSFF{W0GQR1XS
MHH-ES-1	NVXSN4U3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHyxVXdKSzVyPUiuOVE5OzRizszN	M2rEO3NCVkeHUh?=
TE-12	NWPVfHFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4X5PGlEPTB;OD61PVk{OSEQvF2=	NHLYOXVUSU6JRWK=
YH-13	M37Cbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRThwNkGwNFgh\|ryP	M2\1cnNCVkeHUh?=
SF126	Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDoV49KSzVyPUiuPFM5PjVizszN	NILDd5lUSU6JRWK=
J82	M{PBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPP[WFKSzVyPUiuPVAxOzhizszN	NFjocpZUSU6JRWK=
RCC10RGB	M1jxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPORodKSzVyPUiuPVk2PjFizszN	NUjjO\|BZW0GQR1XS
SK-UT-1	M1vkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rrcGlEPTB;OT6wOFk1PSEQvF2=	NXr0Sot7W0GQR1XS
LB2241-RCC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDvTWM2OD17LkG5NVM4KM7:TR?=	MojzV2FPT0WU
LB996-RCC	NXf6TWxET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTlwMUm4PUDPxE1?	NGfKO3hUSU6JRWK=
EPLC-272H	M1K0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DMTmlEPTB;OT6zO\|Y2PyEQvF2=	NFy0W\|RUSU6JRWK=
CTV-1	MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrGXGp2UUN3ME25MlU3PTN{IN88US=>	Ml\GV2FPT0WU
HSC-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DmOmlEPTB;OT61O\|U2KM7:TR?=	NH7HcnRUSU6JRWK=
SK-MEL-28	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLKTWM2OD17Lk[xPFk{KM7:TR?=	MXrTRW5ITVJ?
MMAC-SF	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUO2S417UUN3ME25MlY5PzVizszN	MnHrV2FPT0WU
CP50-MEL-B	MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzxTWM2OD17Lke1O\|gzKM7:TR?=	M4\TXXNCVkeHUh?=
HT-1080	MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1L2XmlEPTB;OT63O\|c{QSEQvF2=	MojOV2FPT0WU
HEC-1	NVrQTYRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzqR4xoUUN3ME2xNE4{OzV{IN88US=>	NUTyZo05W0GQR1XS
AGS	M1P6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTFyLkO3OEDPxE1?	MoTuV2FPT0WU
GAMG	MnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVP3c4lIUUN3ME2xNE42OTZ{IN88US=>	NXzvXG5HW0GQR1XS
SW48	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTFyLkWxPFkh\|ryP	NHnE[plUSU6JRWK=
U031	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHFTWM2OD1zMD61PVA5KM7:TR?=	MlrvV2FPT0WU
OVCAR-5	NXrUXmFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\2cWlEPTB;MUCuOlQzQSEQvF2=	MX\TRW5ITVJ?
SF295	NETOOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknUTWM2OD1zMD62O\|A1KM7:TR?=	NI\0NVRUSU6JRWK=
BHT-101	NVyx[VdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LWZ2lEPTB;MUCuO\|E4PyEQvF2=	M1;WbnNCVkeHUh?=
VMRC-RCZ	NHy1bWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUH1cldPUUN3ME2xNU4{OjBzIN88US=>	NETDTHlUSU6JRWK=
ACHN	NYX3OmNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7TcXNKSzVyPUGxMlQzOTFizszN	MnP1V2FPT0WU
NCI-H526	MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{KwV2lEPTB;MUGuOVA1OyEQvF2=	NFK1OWJUSU6JRWK=
MN-60	M{OxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\ufGlEPTB;MUGuOVM6KM7:TR?=	MULTRW5ITVJ?
NCI-H2291	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTFzLkW0OlYh\|ryP	MmXEV2FPT0WU
SCC-25	M2q1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HmdWlEPTB;MUGuO\|U2PiEQvF2=	NFjh[FBUSU6JRWK=
SK-MEL-2	M4[4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXX5O2d[UUN3ME2xNU44PjN5IN88US=>	NHLZSHFUSU6JRWK=
SN12C	M{\wVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXSU2N[UUN3ME2xNU46OzV3IN88US=>	M3[1XHNCVkeHUh?=
NCI-H69	Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXizOYRnUUN3ME2xNk41OjN2IN88US=>	M{TUNHNCVkeHUh?=
ME-180	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfITHhKSzVyPUGyMlcxPTRizszN	M1m3O3NCVkeHUh?=
MC-IXC	NYPYSmdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTMTWM2OD1zMj63OVE5KM7:TR?=	NUGzWWQ5W0GQR1XS
NCI-H2347	NGnwV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTF{Lke2NVQh\|ryP	NIi3U\|ZUSU6JRWK=
M059J	M1SwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrUTWM2OD1zMj63O\|I4KM7:TR?=	MUPTRW5ITVJ?
A2058	M1\ROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TkbWlEPTB;MUKuPFY5OSEQvF2=	NVradJR6W0GQR1XS
VA-ES-BJ	M2PhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLMNnZ6UUN3ME2xNk45Pzh3IN88US=>	MmPjV2FPT0WU
Ca9-22	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXOTWM2OD1zMj65OFUyKM7:TR?=	NX:5V4Q5W0GQR1XS
KNS-42	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3y4T2lEPTB;MUKuPVk5PCEQvF2=	NXnidmM{W0GQR1XS
LoVo	M{HtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2X2cWlEPTB;MUOuNlMyOyEQvF2=	NHj5XGdUSU6JRWK=
AM-38	M1y2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfhTWM2OD1zMz6yOVY3KM7:TR?=	M4G4XHNCVkeHUh?=
NB5	Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXQbVhPUUN3ME2xN{4{PzV{IN88US=>	MVLTRW5ITVJ?
L-363	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;qTWM2OD1zMz60NFM{KM7:TR?=	M1e0U3NCVkeHUh?=
SK-MEL-30	NHjrN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTF2LkC2OFUh\|ryP	NWn0TpJbW0GQR1XS
NCI-H1563	M4K1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVO4Xo92UUN3ME2xOE43ODN7IN88US=>	M1i1OnNCVkeHUh?=
NCI-H2228	MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnEUYhKSzVyPUG0MlYxPzdizszN	NFnDS4dUSU6JRWK=
MFM-223	NIOybXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fBNWlEPTB;MUWuNVgyOyEQvF2=	MoPJV2FPT0WU
LB831-BLC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HOUWlEPTB;MUWuNlc3PyEQvF2=	NHjxN41USU6JRWK=
SW872	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4iyUWlEPTB;MUWuN\|A5PiEQvF2=	NFzncGxUSU6JRWK=
NCI-H522	MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLVTWM2OD1zNT6zN\|A3KM7:TR?=	M1XGfnNCVkeHUh?=
EW-1	M{DWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2qwXWlEPTB;MUWuOVQ3OiEQvF2=	MlHSV2FPT0WU
HN	MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPK[JpKSzVyPUG1MlU6PDJizszN	M2\h[3NCVkeHUh?=
SW837	M1\CeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PUcmlEPTB;MUWuO\|g1PyEQvF2=	NFrV[FVUSU6JRWK=
SCC-9	NY\UWFZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jT[2lEPTB;MUWuPFEyPCEQvF2=	M{nFVnNCVkeHUh?=
MKN7	NVzyUG1sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofSTWM2OD1zNT65O\|MzKM7:TR?=	M{jNd3NCVkeHUh?=
KYSE-410	Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkT4TWM2OD1zNj61PVEh\|ryP	MXfTRW5ITVJ?
SK-N-DZ	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLnTWM2OD1zNj62NVE3KM7:TR?=	NXr6RphPW0GQR1XS
COR-L105	M2HhU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHEZ2hEUUN3ME2xOk43PTJ6IN88US=>	MY\TRW5ITVJ?
LB2518-MEL	M1\WU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTF4LkizPFkh\|ryP	MVXTRW5ITVJ?
OVCAR-4	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\GTWM2OD1zNj64PFYzKM7:TR?=	NYTteZJCW0GQR1XS
TK10	NX3EUIVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnDdnRKSzVyPUG2Mlk1PzNizszN	M4K3fXNCVkeHUh?=
KNS-62	M2XPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnsTWM2OD1zNj65O\|c4KM7:TR?=	M3vwPHNCVkeHUh?=
RPMI-8866	NEmxU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTQTWM2OD1zNz6xO\|MzKM7:TR?=	MkWwV2FPT0WU
HuP-T4	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjLe5VjUUN3ME2xO{4zPDl3IN88US=>	M2TpVXNCVkeHUh?=
CGTH-W-1	MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnyN2pKSzVyPUG3MlUzOTlizszN	NX70VmNPW0GQR1XS
T-24	M3LLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTF5LkWzOFch\|ryP	NIPNdmVUSU6JRWK=
HT-3	NIr2[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVf4VXhIUUN3ME2xO{42QTF2IN88US=>	NU\pSFVKW0GQR1XS
KS-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFX5fWlKSzVyPUG3MlY4OyEQvF2=	MkOxV2FPT0WU
NCI-H1792	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTF5Lke5PEDPxE1?	MoniV2FPT0WU
ABC-1	M3fUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\JSYpTUUN3ME2xO{45OTRzIN88US=>	MnzNV2FPT0WU
BPH-1	MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnaRoRKSzVyPUG4MlE3QDVizszN	MofVV2FPT0WU
A431	Ml\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHRflVKSzVyPUG4MlQyOjdizszN	NIjOZ3RUSU6JRWK=
T98G	M4jWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\ZfmlEPTB;MUiuOVE2PyEQvF2=	NYPj[GU{W0GQR1XS
BHY	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHwTWM2OD1zOD64Olkh\|ryP	MW\TRW5ITVJ?
Capan-2	MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDETWM2OD1zOD65NFc5KM7:TR?=	NHvadYhUSU6JRWK=
MDA-MB-175-VII	M3zIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3ixTGlEPTB;MUiuPVIxQSEQvF2=	NXvORZpIW0GQR1XS
CAL-27	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVL4R2N2UUN3ME2xPU4xPDh5IN88US=>	MVrTRW5ITVJ?
AsPC-1	NYLUW3d4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3jNpprUUN3ME2xPU45PjV5IN88US=>	MYHTRW5ITVJ?
KU812	Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTF7Lkm1O\|Mh\|ryP	MV7TRW5ITVJ?
NCI-H441	NIGyW\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrIc41{UUN3ME2yNE4xODFizszN	Mn:4V2FPT0WU
Mewo	MnrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XHOWlEPTB;MkCuNVI5QCEQvF2=	NVvKeYhpW0GQR1XS
SK-MEL-24	MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXoSpFKSzVyPUKwMlE1PzdizszN	MXzTRW5ITVJ?
NCI-H727	MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTJyLkK3NFQh\|ryP	NUTaRmtlW0GQR1XS
EKVX	NVLxXmpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfkTWM2OD1{MD62NFYh\|ryP	NHz3b4FUSU6JRWK=
RT-112	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rS[mlEPTB;MkCuOlEzOiEQvF2=	NXXTTYl5W0GQR1XS
CAMA-1	NV\MTmpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHobYNKSzVyPUKwMlk5ODNizszN	MnvhV2FPT0WU
SW900	MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TIc2lEPTB;MkGuNFE1QSEQvF2=	M3;mN3NCVkeHUh?=
NCI-H23	NGDpOJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzCdY9KSzVyPUKxMlEzPzdizszN	NXXu[pNXW0GQR1XS
SK-PN-DW	NELC[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4S0fmlEPTB;MkGuNVY1QSEQvF2=	MWrTRW5ITVJ?
BB30-HNC	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTJzLkK3OFUh\|ryP	Mm\rV2FPT0WU
VM-CUB-1	Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkC4TWM2OD1{MT6zOVM3KM7:TR?=	Mn[zV2FPT0WU
IST-MEL1	MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTJzLkO2PVIh\|ryP	M3zwdnNCVkeHUh?=
CTB-1	NEjtTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXuTWM2OD1{MT60O\|U2KM7:TR?=	M4jXNXNCVkeHUh?=
LCLC-103H	M2LseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TlRmlEPTB;MkKuNVU5OiEQvF2=	MnraV2FPT0WU
PANC-03-27	NH;rfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTJ{LkWxOlkh\|ryP	M3Pxc3NCVkeHUh?=
HTC-C3	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPkRWtKSzVyPUKyMlU2PTVizszN	NIXOWmdUSU6JRWK=
TE-8	M17nN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLkTWM2OD1{Mz6yOVY2KM7:TR?=	M{juZnNCVkeHUh?=
NCI-H292	M2HMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jxfGlEPTB;MkWuN\|U{PiEQvF2=	M2PZTHNCVkeHUh?=
COLO-680N	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTJ3Lk[zNlkh\|ryP	M{[1eXNCVkeHUh?=
KYSE-520	Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEn0TIVKSzVyPUK1MlY1PCEQvF2=	M4ezNHNCVkeHUh?=
NB10	NX\DUnRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjpbmhNUUN3ME2yOk4{OTF5IN88US=>	M3;FTXNCVkeHUh?=
NCI-H661	MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTJ4LkS3NVMh\|ryP	NIX3UW5USU6JRWK=
GMS-10	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlm0TWM2OD1{Nj64OlM5KM7:TR?=	NF3zR4hUSU6JRWK=
NCI-H2122	M1vPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTZTWM2OD1{Nj65PVk5KM7:TR?=	M2rKSXNCVkeHUh?=
OVCAR-8	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3rRVEyUUN3ME2yO{4xPjN6IN88US=>	MoOwV2FPT0WU
DJM-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjScnNKSzVyPUK3MlE1PTRizszN	NGfPZ5NUSU6JRWK=
UACC-893	NUjINJlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TSZmlEPTB;MkeuPVg4QCEQvF2=	NFTa[VRUSU6JRWK=
C8166	M4fxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHWXmVPUUN3ME2yPE43QTN6IN88US=>	Ml35V2FPT0WU
NCI-H1693	NVK4cldlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;KNmlEPTB;MkiuOlk4PSEQvF2=	NH\6cIpUSU6JRWK=
TYK-nu	MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;JTWM2OD1\|MD6wN\|Q2KM7:TR?=	MVrTRW5ITVJ?
SW1710	MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3r2bGlEPTB;M{CuNVI3KM7:TR?=	MVLTRW5ITVJ?
A375	M4HhUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHe2V5ZKSzVyPUOwMlMzPDNizszN	MUHTRW5ITVJ?
HMV-II	MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTNzLkO1PVIh\|ryP	MXHTRW5ITVJ?
NCI-H2087	NXq2b2dQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fic2lEPTB;M{GuOlM2OiEQvF2=	M1zZcHNCVkeHUh?=
CAL-54	NF;XUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DQVmlEPTB;M{GuO\|I1OSEQvF2=	NWi4VWNjW0GQR1XS
HCC70	M1GyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvsepdwUUN3ME2zNk4yOzh5IN88US=>	MYjTRW5ITVJ?
ES1	NYXOdHU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfCU3ZKSzVyPUOyMlMxPjJizszN	NXPYPXBWW0GQR1XS
NCI-H1355	M3LCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4m5bmlEPTB;M{OuNlA1KM7:TR?=	M2DrXXNCVkeHUh?=
CFPAC-1	M320OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFu0N2tKSzVyPUOzMlI{OzJizszN	M3LvPXNCVkeHUh?=
MKN28	MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTN\|LkO4NFkh\|ryP	MnLCV2FPT0WU
HDLM-2	NGX0d49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXFd5VKSzVyPUOzMlY6OzFizszN	NY\Ud3FXW0GQR1XS
PANC-10-05	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHr0S3BKSzVyPUO0MlExOTRizszN	MWjTRW5ITVJ?
SAS	MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTjeGt5UUN3ME2zOE41PTZ3IN88US=>	MVfTRW5ITVJ?
HCC1395	NFTaeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnNToJKSzVyPUO0MlcyQDZizszN	MlzPV2FPT0WU
8305C	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnKTWM2OD1\|NT64OFE2KM7:TR?=	M4fEXXNCVkeHUh?=
KM12	M1vGTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDTZpFKSzVyPUO2Mlc2PDdizszN	M{nC[HNCVkeHUh?=
SW1116	NWL3WGd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTN5LkW5PVIh\|ryP	NGG4bXdUSU6JRWK=
SK-MEL-1	NHfvSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2CzVmlEPTB;M{iuN\|M5QSEQvF2=	NGHRRo9USU6JRWK=
HCC2218	NHLzcJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvGZ5hUUUN3ME2zPE43PTF7IN88US=>	NFjmWGRUSU6JRWK=
T84	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7VTWM2OD1\|OD63OFA6KM7:TR?=	MX;TRW5ITVJ?
ETK-1	Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGruW3dKSzVyPUO5MlAzOiEQvF2=	NXyxU4dZW0GQR1XS
COLO-800	NWS2XoY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTN7LkO4Olgh\|ryP	NVLlOXlJW0GQR1XS
CAL-12T	MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLLUlNEUUN3ME2zPU42OjhzIN88US=>	MVHTRW5ITVJ?
ACN	NFq0XJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3yTJRKSzVyPUSwMlQ6OTFizszN	MUXTRW5ITVJ?
SJSA-1	NEjqNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjUNWpiUUN3ME20NU4yPTl4IN88US=>	NH3OW2dUSU6JRWK=
PSN1	MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLRWo1iUUN3ME20NU4yPzR7IN88US=>	M4LzXHNCVkeHUh?=
D-566MG	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLkRWZKSzVyPUSxMlIxQDZizszN	MmPWV2FPT0WU
EGI-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfzUFJJUUN3ME20Nk41OjhizszN	M{DycHNCVkeHUh?=
A204	NIPxfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7FTWM2OD12Mj62N\|g5KM7:TR?=	M3vwVnNCVkeHUh?=
Saos-2	Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37PdGlEPTB;NEKuPFM3QSEQvF2=	NXLMUI9rW0GQR1XS
SNU-C2B	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rkbmlEPTB;NEOuOlg4QCEQvF2=	MkiyV2FPT0WU
HLE	NV;ZR\|dPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnkTWM2OD12ND6wPFU3KM7:TR?=	MXTTRW5ITVJ?
SW1463	MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfHdZhKSzVyPUS0Mlk6PzFizszN	NEXEd3lUSU6JRWK=
DSH1	NIXUUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTLTWM2OD12NT6wNFM{KM7:TR?=	NEDSZYVUSU6JRWK=
MCF7	M2PXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHROHlKSzVyPUS1MlUxPTFizszN	MmDzV2FPT0WU
K5	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnaWoNMUUN3ME20OU46PDB3IN88US=>	Mke0V2FPT0WU
NCI-H358	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWD2NGlsUUN3ME20O{4zOTVizszN	NIf0eGFUSU6JRWK=
NCI-H2030	Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYWzbZQ4UUN3ME20O{4zOzd2IN88US=>	M1qw[HNCVkeHUh?=
SW948	NIr0UmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTR5LkS2OEDPxE1?	NHLOfZpUSU6JRWK=
BALL-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHu1TWtKSzVyPUS3MlYyPjhizszN	NHf2O4RUSU6JRWK=
TE-9	MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\sTWM2OD12Nz65OVgyKM7:TR?=	NYr2PHlrW0GQR1XS
SK-N-FI	NYT2cHU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfiNJZKSzVyPUS4MlA{PThizszN	MkXhV2FPT0WU
KALS-1	NULPTo54T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfWU21OUUN3ME20PE4yOjh7IN88US=>	M4DGWnNCVkeHUh?=
HO-1-N-1	MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1v5VGlEPTB;NEiuO\|Q1PSEQvF2=	NUC2R5puW0GQR1XS
NCI-H2452	MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXkTWM2OD12OT6xNVUzKM7:TR?=	MWPTRW5ITVJ?
OC-314	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTR7Lk[4N\|Qh\|ryP	M3HGcHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; PubMed: 26811457 Proc Natl Acad Sci U S A (A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control. caspase3 / cleaved caspase 3; PubMed: 24481442 Cell Death Dis (b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa).	26811457 24481442
Growth inhibition assay	Cell viability; PubMed: 25685063 Cancer Cell Int (C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.	25685063

体内研究

用ABT-263处理H345移植瘤模型，按动物体重，每千克每天处理10mg ABT-263，结果肿瘤生长抑制率达80% ，肿瘤体积减小了50%以上，显示出ABT-263极强的抗癌效果。ABT-263作用于非小细胞肺癌和急性淋巴细胞白血病的移植瘤模型时，每天单独口服，结果显示肿瘤完全衰退。ABT-263单独作用于B-细胞淋巴瘤和多发性骨髓瘤的移植瘤模型时效果不明显，但是可以显著增强临床其他相关用药的药性。^[2]

激酶实验： ^[1]	- 合并激酶实验: 用竞争性荧光偏振检测测定ABT-263 作用于Bcl-2 家族不同亚型的Ki值或者IC50值。使用如下的肽探针对或者蛋白对：f-bad (1 nM) 和Bcl-xL (6 nM), f-Bax (1 nM) 和Bcl-2 (10 nM), f-Bax (1 nM) 和Bcl-w (40 nM), f-Noxa (2 nM)和Mcl-1 (40 nM), 及f-Bax (1 nM) 和Bcl-2-A1 (15 nM)。用时间分辨荧光共振能转移法测定ABT-263和Bcl-xL作用的结合紧密度。1 nM 用His标记的Bcl-xL 与200 nM f-Bak,及 1 nM Tb标记的His抗体混合, 然后在室温下处理30分钟。
细胞实验： ^[1]	- 合并 Cell lines: SCLC 细胞系 Concentrations: 0-1 μM Incubation Time: 48小时 Method: 人类肿瘤细胞系在37^oC 含5% CO₂环境下获得，SCLC 细胞系培养在RPMI 1640培养基中，培养基包含10% 胎牛血清, 1% 丙酮酸钠, 25 mM HEPES, 4.5 g/L葡萄糖, 1% 青霉素/链霉素。用含有10% FBS和1% 青霉素/链霉素的RPMI 1640培养基培养白血病和淋巴癌细胞系。细胞在96孔板上处理48小时，最终体积达到100ul。在体外测试ABT-263的细胞毒性。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: C.B.-17严重联合免疫缺陷-米黄鼠 Formulation: ABT-263在10% 乙醇, 30% 聚乙二醇400, 及60% Phosal 50 PG中制成 Dosages: 100 mg/kg/d Administration: 口服处理 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+corn oil	7mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Navitoclax (ABT-263) SDF

分子量	974.61
化学式	C₄₇H₅₅ClF₃N₅O₆S₃
CAS号	923564-51-6
储存条件	3年 -20°C粉状
储存条件	2年 -80°C 溶于溶剂
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03181126	Recruiting	Drug: Navitoclax\|Drug: Chemotherapy\|Drug: Venetoclax	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 27 2017	Phase 1
NCT02520778	Recruiting	Drug: Navitoclax\|Drug: Osimertinib	Advanced Lung Non-Squamous Non-Small Cell Carcinoma\|EGFR Exon 19 Deletion Mutation\|EGFR NP_005219.2:p.L858R\|EGFR NP_005219.2:p.T790M\|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma\|Stage III Lung Non-Small Cell Cancer AJCC v7\|Stage IIIA Lung Non-Small Cell Cancer AJCC v7\|Stage IIIB Lung Non-Small Cell Cancer AJCC v7\|Stage IV Lung Non-Small Cell Cancer AJCC v7	National Cancer Institute (NCI)	March 31 2016	Phase 1
NCT02591095	Completed	Drug: ABT-263	Platinum-resistant or Refractory Ovarian Cancer	Centre Francois Baclesse\|ARCAGY/ GINECO GROUP\|French Cancer Research Hospital Program	January 2016	Phase 2
NCT02079740	Recruiting	Biological: Navitoclax\|Drug: Trametinib	Advanced Malignant Solid Neoplasm\|Malignant Female Reproductive System Neoplasm\|Metastatic Malignant Solid Neoplasm\|Recurrent Lung Carcinoma\|Recurrent Malignant Solid Neoplasm\|Recurrent Pancreatic Carcinoma\|Stage III Lung Cancer AJCC v7\|Stage III Pancreatic Cancer AJCC v6 and v7\|Stage IV Lung Cancer AJCC v7\|Stage IV Pancreatic Cancer AJCC v6 and v7\|Unresectable Malignant Solid Neoplasm	National Cancer Institute (NCI)	March 7 2014	Phase 1\|Phase 2
NCT00887757	Completed	Drug: ABT-263\|Drug: gemcitabine	Solid Tumors	AbbVie\|Genentech Inc.	September 2009	Phase 1
NCT00888108	Completed	Drug: ABT-263\|Drug: Docetaxel	Solid Tumor	Abbott\|Genentech Inc.	July 2009	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
回答：
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
问题 2：
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
回答：
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

选择性强的Bcl-2抑制剂

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
用于临床的Bcl-2抑制剂

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
最新的Bcl-2家族激活剂

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
经典的Bcl-2抑制剂

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

研究领域

产品类型

Navitoclax (ABT-263)

客户使用Selleck该产品发表文献153篇：

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Navitoclax (ABT-263) SDF

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

技术支持

常见问题及建议解决方法

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

相关Bcl-2产品